Allergy Immunotherapy Market Trends

Growth Drivers

• Government funding activities: One of the major factors driving growth in the allergy immunotherapy sector is the increasing funding from government and public healthcare initiatives. According to the Research Gate report released in April 2021, allergy immunotherapy costs range from USD 748 to USD 849, with many claims exceeding USD 1,000. Additionally, the regulatory frameworks, such as the U.S. FDA, support with needed approvals in supporting the development of innovative immunotherapy products, enabling greater affordability for treatments.
• Advancements in personalized medicine: Another major factor driving growth in the allergy immunotherapy market is the innovative and personalized therapeutic measures. This ability to customize the management relying on the patient's medical profile has created immense awareness due to its higher efficacy and low side effects. As per the NLM report in November 2024, allergy immunotherapy demonstrates significantly improved effectiveness compared to traditional methods, with effectiveness improvements of approximately 30%. This global shift is expected to improve patient outcomes and boost the market demand.
• Increasing disease incidence: The allergy immunotherapy is increasing global incidence of allergic rhinitis and asthma, due to urbanization, air pollution, and climate change prolonging pollen seasons. Many people are impacted in North America and Europe alone. For instance, more than 40% of pediatric patients have allergic rhinitis and develop symptoms before 6years, giving AIT access to a huge and expanding treatable patient base, based on the frontiers article in April 2022. This superior prevalence guarantees a stable and increasing baseline need for subcutaneous (SCIT) and sublingual (SLIT) immunotherapy treatments.

Percentage of Allergy Dragonized in Adults in 2021

Source: CDC January 2023

Challenge

• Uneven market access: One of the major challenges posed by the market is the uneven market access, particularly in the emerging regions. This is mainly influenced by expensive therapeutic costs associated with allergic immunotherapy and a lack of public awareness, which makes it difficult for the products to reach the targeted group of patients. Additionally, the products from allergy immunotherapy are often unavailable in the rural areas of developing regions due to their high costs and low insurance subsidies, thereby hindering market upliftment.